×
N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marke...
https://doi.org/10.1002/jmv.26541
Journal of Medical Virology; Yue L, Cao H et. al.

Sep 23rd, 2020 - The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) had led to a serious public health crisis, and no specific treatments or vaccines are available yet. A nucleocapsid protein (NP)-based enzyme-linked immunosorbent assay (ELISA) detection method is not only important in disease diagnosis, but is required for the evaluation of vaccine effi...

COVID-19 confirmed patients with negative antibodies results.
https://doi.org/10.1186/s12879-020-05419-3
BMC Infectious Diseases; Wang J, Chen C et. al.

Sep 23rd, 2020 - A new coronavirus disease 2019 (COVID-19) has escalated to a pandemic since its first outbreak in Wuhan, China. A small proportion of patients may have difficulty in generating IgM or IgG antibodies against SARS-CoV-2, and little attention has been paid to them. We present two cases of confirmed COVID-19 patients and characterize their initial symptoms, chest CT results, medication, and laborat...

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infectio...
https://doi.org/10.1017/ice.2020.1220
Infection Control and Hospital Epidemiology; Dimcheff DE, Schildhouse RJ et. al.

Sep 23rd, 2020 - The seroprevalence of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) IgG antibody was evaluated among employees of a Veterans Affairs Healthcare System to assess potential risk factors for transmission and infection. All employees were invited to participate in a questionnaire and serological survey to detect antibodies to SARS-CoV-2 M protein as part of a facility-wide quality im...

Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19 | FDA
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-point-care-antibody-test-covid-19

Sep 23rd, 2020 - For Immediate Release: September 23, 2020 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19. The Assure COVID-19 IgG/IgM Rapid Test Device was first authorized for emergency use by certain labs in July 2020 to help identify individuals with antibodies to SARS-CoV-2, indicating recent o...

Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease.
https://doi.org/10.1182/blood.2020008423
Blood Hueso T, Pouderoux C et. al.

Sep 22nd, 2020 - Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies or autoimmune disease but may be responsible for a secondary humoral deficiency. In the context of COVID-19 infection, this may prevent the elicitation of a specific SARS-CoV-2-antibody response. We report a series of 17 consecutive patients with profound B-cell lymphopenia and prolonged COVID-19 sym...

ANNALS EXPRESS: Performance verification of COVID-19-specific antibody detection by usi...
https://doi.org/10.1177/0004563220963847
Annals of Clinical Biochemistry; Wan Y, Li Z et. al.

Sep 22nd, 2020 - The purpose of the current study was to evaluate the analytical performance of seven kits for detecting IgM/IgG antibodies against coronavirus (SARS-CoV-2) by using four chemiluminescence immunoassay systems. Fifty patients diagnosed with SARS-CoV-2 infection and 130 controls without coronavirus infection from the General Hospital of Chongqing were enrolled in the current retrospective study. F...

Perspectives on development of vaccines against severe acute respiratory syndrome coron...
https://doi.org/10.1080/21645515.2020.1787064
Human Vaccines & Immunotherapeutics; Zhang C, Zhou C et. al.

Sep 22nd, 2020 - The recent outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been characterized by the World Health Organization (WHO) as a controllable global pandemic. The spike (S) glycoprotein mediates binding to the angiotensin-converting enzyme 2 (ACE2) receptor for virus entry and also services as the target of virus-neut...

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device ...
https://doi.org/10.1016/j.jcv.2020.104645
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology; Batra R, Olivieri LG et. al.

Sep 22nd, 2020 - Antibodies to SARS-CoV-2 serve as critical diagnostic markers for determining how broadly the COVID-19 pandemic has spread, confirming patient recovery, monitoring potential long-term effects of infection, and evaluating potential protection from reinfection. As new antibody tests become available, it is important to evaluate their performance and utility. The aim of this study was to compare t...

Clinical characteristics and humoral immune response in Healthcare Workers with COVID-1...
https://doi.org/10.1016/j.jhin.2020.09.018
The Journal of Hospital Infection; Vandercam G, Simon A et. al.

Sep 21st, 2020 - Healthcare workers (HCWs) are at high risk of acquiring COVID-19 and could play a role in nosocomial transmission. Since February 4, 2020, Belgian Health authorities reported more than 90568 cases, of which 8.3% were HCWs. Data on clinical characteristics, sources of infection and humoral immune response of HCWs with COVID-19 remain scarce. Analyse the clinical characteristics, humoral immune r...

ESPGHAN 'biopsy-sparing' guidelines for celiac disease in children with low antitransgl...
https://doi.org/10.1097/MEG.0000000000001924
European Journal of Gastroenterology & Hepatology; Trovato CM, Montuori M et. al.

Sep 21st, 2020 - Recent guidelines for celiac disease have allowed a biopsy-free approach in endomysial antibodies (EMAs) positive children with high antitransglutaminase (TGA-IgA) titer [>10 time upper limit of normal (ULN)]. Esophagogastroduodenoscopy is still necessary for diagnosis in children with lower title. Because elective pediatric endoscopy has been substantially shouted down during coronavirus disea...

SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel...
https://doi.org/10.3201/eid2612.203764
Emerging Infectious Diseases; Akinbami LJ, Vuong N et. al.

Sep 21st, 2020 - To estimate seroprevalence of severe acute respiratory syndrome 2 (SARS-CoV-2) among healthcare, first response, and public safety personnel, antibody testing was conducted in emergency medical service agencies and 27 hospitals in the Detroit, Michigan, USA, metropolitan area during May-June 2020. Of 16,403 participants, 6.9% had SARS-CoV-2 antibodies. In adjusted analyses, seropositivity was a...

An update on COVID-19 infection control measures, plasma-based therapeutics, corticoste...
https://doi.org/10.1016/j.transci.2020.102934
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for HaemApheresis; Putter JS, Seghatchian J

Sep 19th, 2020 - This communication provides a compilation on aspects of COVID-19 infection control measures, describes the potential role of therapeutic plasma exchange to reduce fatality rates, addresses precautions concerning dexamethasone pharmacotherapy and updates the current status on the availability of vaccines. As part of passive immunotherapy, it focuses on various blood derivatives. These include co...

Combined anti-SARS-CoV-2 IgA, IgG, and IgM Detection as a Better Strategy to Prevent Se...
https://doi.org/10.1080/08820139.2020.1823407
Immunological Investigations; Nuccetelli M, Pieri M et. al.

Sep 18th, 2020 - Coronavirus disease (COVID-19) is challenging many health, economic, and social systems. RT-PCR assays are diagnosis gold standard; however, they can lead to false-negative results. Therefore, anti-SARS-CoV-2 IgG, IgM, and IgA investigation can play a complementary role in assessing the individuals immune status. Majority of serological tests focus on IgM and IgG although IgA are the main immun...

Investigation of immune cells on elimination of pulmonary-Infected COVID-19 and importa...
https://doi.org/10.1002/rmv.2158
Reviews in Medical Virology REFERENCES; Farshi E, Kasmapur B et. al.

Sep 18th, 2020 - We identified types of immune cells that contribute to clearing COVID-19 during the acute phase of the infection in mouse model and human. Our results suggest that both innate and adaptive immune responses are essential for controlling COVID-19 infection. Mild infection report of children by COVID-19 comparing adults' infection causes conclusion of higher resistance of immune system of children...

Covid-19 and dengue: Double punches for dengue-endemic countries in Asia.
https://doi.org/10.1002/rmv.2161
Reviews in Medical Virology REFERENCES; Harapan H, Ryan M et. al.

Sep 18th, 2020 - The coronavirus disease 2019 (Covid-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an international public health crisis with devastating effects. In particular, this pandemic has further exacerbated the burden in tropical and subtropical regions of the world, where dengue fever, caused by dengue virus (DENV), is already endemic to the population. The s...

Systemic complement activation is associated with respiratory failure in COVID-19 hospi...
https://doi.org/10.1073/pnas.2010540117
Proceedings of the National Academy of Sciences of the United States of America; Holter JC, Pischke SE et. al.

Sep 18th, 2020 - Respiratory failure in the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is hypothesized to be driven by an overreacting innate immune response, where the complement system is a key player. In this prospective cohort study of 39 hospitalized coronavirus disease COVID-19 patients, we describe systemic complement activation and its association with development of respiratory fail...

COVID-19 Coagulopathy in a Patient With Systemic Lupus Erythematosus and Antiphospholip...
https://doi.org/10.1097/RHU.0000000000001599
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases; Freeman-Beman L, Ratner S et. al.

Sep 18th, 2020 - COVID-19 Coagulopathy in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Antibodies.|2020|Freeman-Beman L,Ratner S,Kabani N,Neculiseanu E,Ginzler E,|

Value and Validity of Coronavirus Antibody Testing.
https://www.ncbi.nlm.nih.gov/pubmed/32942795
Pain Physician; Mahajan A, Manchikanti L

Sep 18th, 2020 - The interventional pain management community saw the COVID-19 pandemic decimate elective interventional procedures and new patient visits across the United States until the reopening of America and the restarting of interventional procedures and elective surgical procedures began again. Health care providers, along with essential workers and patients, continue to be concerned about functioning ...

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.
https://doi.org/10.1038/s41467-020-18468-8
Nature Communications; Ng DL, Goldgof GM et. al.

Sep 18th, 2020 - Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April...

Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain...
https://doi.org/10.1016/j.ctrv.2020.102102
Cancer Treatment Reviews; Cabezón-Gutiérrez L, Custodio-Cabello S et. al.

Sep 18th, 2020 - Coronavirus disease in 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has emerged as a global pandemic. Published data suggests that patients with a history of or active malignancy are at increased risk of infection and developing COVID-19 related complications. To date, the published data has analyzed the seroprevalence of COVID-19 infection in the gener...